Shopping Cart

Actinic Solar Keratosis-Pipeline Review, H1 2016

SKU
GMDHC7723IDB
READ MORE
USD 2,000
Single User License
USD 2,000
Site License
USD 4,000
Corporate User License
USD 6,000

Summary

Global Markets Direct's, 'Actinic (Solar) Keratosis-Pipeline Review, H1 2016', provides an overview of the Actinic (Solar) Keratosis pipeline landscape.

The report provides comprehensive information on the therapeutics und

READ MORE
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Summary

Global Markets Direct's, 'Actinic (Solar) Keratosis-Pipeline Review, H1 2016', provides an overview of the Actinic (Solar) Keratosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis

The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects

The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Actinic (Solar) Keratosis Overview 9

Therapeutics Development 10

Pipeline Products for Actinic (Solar) Keratosis-Overview 10

Pipeline Products for Actinic (Solar) Keratosis-Comparative Analysis 11

Actinic (Solar) Keratosis-Therapeutics under Development by Companies 12

Actinic (Solar) Keratosis-Therapeutics under Investigation by Universities/Institutes 14

Actinic (Solar) Keratosis-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Actinic (Solar) Keratosis-Products under Development by Companies 19

Actinic (Solar) Keratosis-Products under Investigation by Universities/Institutes 21

Actinic (Solar) Keratosis-Companies Involved in Therapeutics Development 22

3M Drug Delivery Systems 22

Athenex, Inc. 23

Biofrontera AG 24

Digna Biotech, S.L. 25

Dolorgiet Gmbh & Co. Kg 26

Foamix Pharmaceuticals Ltd. 27

G&E Herbal Biotechnology Co., Ltd. 28

Galderma S.A. 29

Laboratories Ojer Pharma S.L. 30

LEO Pharma A/S 31

Novartis AG 32

Novelix Pharmaceuticals, Inc. 33

Oncology Research International Limited 34

Promius Pharma, LLC 35

SkyePharma Plc 36

Spherium Biomed S.L. 37

Valeant Pharmaceuticals International, Inc. 38

Actinic (Solar) Keratosis-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Combination Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

ACT-01-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

AD-17137-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AK-3012-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

aminolevulinic acid hydrochloride-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

celecoxib-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

DFD-08-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

disitertide-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

hydrogen peroxide + sulindac-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

IDP-125-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

IDP-128-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

imiquimod-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

imiquimod SR-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

KX-01-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

LEO-43204-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

LFX-453-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

NVX-207-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

ORIL-007-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Recombinant Peptide for Dermatology, Immunology and Oncology-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

resiquimod-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

SKP-024-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Small Molecule to Agonize TLR-7 and TLR-8 for Oncology, Allergic Rhinitis, Actinic Keratosis and Warts-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Small Molecules to Activate Protein Kinase C for Dermatology and Oncology-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

SP-12054-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

SRT-100-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

VPE-001-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Actinic (Solar) Keratosis-Recent Pipeline Updates 79

Actinic (Solar) Keratosis-Dormant Projects 85

Actinic (Solar) Keratosis-Discontinued Products 87

Actinic (Solar) Keratosis-Product Development Milestones 88

Featured News & Press Releases 88

Feb 11, 2016: Biofrontera Announces, Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer 88

Jan 26, 2016: FDA completes Biofrontera's Ameluz NDA mid-cycle review 89

Dec 07, 2015: Swissmedic grants marketing approval for Ameluz in Switzerland 89

Oct 02, 2015: FDA determines May 10, 2016 as PDUFA date for Ameluz 89

Sep 22, 2015: Excellent long-term outcome with field treatment of actinic keratosis with Ameluz 90

Jun 22, 2015: Biofrontera completes final steps ahead of FDA New Drug Application in the USA 91

May 06, 2015: Biofrontera delivers excellent results from the Phase III study for field therapy of actinic keratosis for publication 91

Mar 25, 2015: Biofrontera starts Sales and Marketing of Ameluz in Spain 92

Jan 26, 2015: Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz 92

Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 93

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95


List Of Figure

List of Figures

Number of Products under Development for Actinic (Solar) Keratosis, H1 2016 10

Number of Products under Development for Actinic (Solar) Keratosis-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Number of Products under Investigation by Universities/Institutes, H1 2016 14

Comparative Analysis by Late Stage Development, H1 2016 15

Comparative Analysis by Clinical Stage Development, H1 2016 16

Comparative Analysis by Early Stage Products, H1 2016 17

Assessment by Monotherapy Products, H1 2016 39

Number of Products by Top 10 Targets, H1 2016 41

Number of Products by Stage and Top 10 Targets, H1 2016 41

Number of Products by Top 10 Mechanism of Actions, H1 2016 43

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 43

Number of Products by Routes of Administration, H1 2016 45

Number of Products by Stage and Routes of Administration, H1 2016 45

Number of Products by Molecule Types, H1 2016 47

Number of Products by Stage and Molecule Types, H1 2016 47


List Of Table

List of Tables

Number of Products under Development for Actinic (Solar) Keratosis, H1 2016 10

Number of Products under Development for Actinic (Solar) Keratosis-Comparative Analysis, H1 2016 11

Number of Products under Development by Companies, H1 2016 13

Number of Products under Investigation by Universities/Institutes, H1 2016 14

Comparative Analysis by Late Stage Development, H1 2016 15

Comparative Analysis by Clinical Stage Development, H1 2016 16

Comparative Analysis by Early Stage Development, H1 2016 17

Comparative Analysis by Unknown Stage Development, H1 2016 18

Products under Development by Companies, H1 2016 19

Products under Development by Companies, H1 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2016 21

Actinic (Solar) Keratosis-Pipeline by 3M Drug Delivery Systems, H1 2016 22

Actinic (Solar) Keratosis-Pipeline by Athenex, Inc., H1 2016 23

Actinic (Solar) Keratosis-Pipeline by Biofrontera AG, H1 2016 24

Actinic (Solar) Keratosis-Pipeline by Digna Biotech, S.L., H1 2016 25

Actinic (Solar) Keratosis-Pipeline by Dolorgiet Gmbh & Co. Kg, H1 2016 26

Actinic (Solar) Keratosis-Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 27

Actinic (Solar) Keratosis-Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016 28

Actinic (Solar) Keratosis-Pipeline by Galderma S.A., H1 2016 29

Actinic (Solar) Keratosis-Pipeline by Laboratories Ojer Pharma S.L., H1 2016 30

Actinic (Solar) Keratosis-Pipeline by LEO Pharma A/S, H1 2016 31

Actinic (Solar) Keratosis-Pipeline by Novartis AG, H1 2016 32

Actinic (Solar) Keratosis-Pipeline by Novelix Pharmaceuticals, Inc., H1 2016 33

Actinic (Solar) Keratosis-Pipeline by Oncology Research International Limited, H1 2016 34

Actinic (Solar) Keratosis-Pipeline by Promius Pharma, LLC, H1 2016 35

Actinic (Solar) Keratosis-Pipeline by SkyePharma Plc, H1 2016 36

Actinic (Solar) Keratosis-Pipeline by Spherium Biomed S.L., H1 2016 37

Actinic (Solar) Keratosis-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 38

Assessment by Monotherapy Products, H1 2016 39

Assessment by Combination Products, H1 2016 40

Number of Products by Stage and Target, H1 2016 42

Number of Products by Stage and Mechanism of Action, H1 2016 44

Number of Products by Stage and Route of Administration, H1 2016 46

Number of Products by Stage and Molecule Type, H1 2016 48

Actinic (Solar) Keratosis Therapeutics-Recent Pipeline Updates, H1 2016 79

Actinic (Solar) Keratosis-Dormant Projects, H1 2016 85

Actinic (Solar) Keratosis-Dormant Projects (Contd..1), H1 2016 86

Actinic (Solar) Keratosis-Discontinued Products, H1 2016 87

To know more information on Purchase by Section, please send a mail to

Products

Actinic (Solar) Keratosis Therapeutic Products under Development, Key Players in Actinic (Solar) Keratosis Therapeutics, Actinic (Solar) Keratosis Pipeline Overview, Actinic (Solar) Keratosis Pipeline, Actinic (Solar) Keratosis Pipeline Assessment

Companies

3M Drug Delivery Systems Athenex, Inc. Biofrontera AG Digna Biotech, S.L. Dolorgiet Gmbh & Co. Kg Foamix Pharmaceuticals Ltd. G&E Herbal Biotechnology Co., Ltd. Galderma S.A. Laboratories Ojer Pharma S.L. LEO Pharma A/S Novartis AG Novelix Pharmaceuticals, Inc. Oncology Research International Limited Promius Pharma, LLC SkyePharma Plc Spherium Biomed S.L. Valeant Pharmaceuticals International, Inc.

Brand Description
History Color sit amet, consectetur adipiscing elit. In gravida pellentesque ligula, vel eleifend turpis blandit vel. Nam quis lorem ut mi mattis ullamcorper ac quis dui. Vestibulum et scelerisque ante, eu sodales mi. Nunc tincidunt tempus varius. Integer ante dolor, suscipit non faucibus a, scelerisque vitae sapien.